Event

Debate: Patients on low-efficacy DMTs should be allowed to switch to a high-efficacy DMT without having to wait for a relapse or progression.


10 Oct 2022 12:00 - 13:00

Please note: There is restricted access to the live webinars. Access to the live webinars is for health professionals working in MS services and a limited number of MS charity representatives and pharmaceutical representatives. If you are not granted access to the live webinar, you will be able to review the footage, which will be posted on our website shortly after the webinar has been conducted.

MS Academy will host a live webinar on Monday, 10 October at 12:00 GMT. You are invited to watch the webinar from your computer, tablet or phone. We will be live for 1 hour via Zoom and a recording will be available following the meeting.

There are a whole range of challenging, even controversial topics around the management of MS at present. Rather than one clear cut answer to these challenges, there are often several perspectives with a variety of evidence in support of each.

So, with that in mind, come and join our latest live debate chaired by Dr David Paling. Dr Sharmilee Gnanapavan will be arguing that patients on low-efficacy DMTs should be allowed to switch to a high-efficacy DMT without having to wait for a relapse or progression, whilst the counter argument will be presented by Dr Antonio Scalfari.

Following this, our chair and speakers will be joined by clinical nurse specialist Jennifer Slough and lead neuroscience pharmacist Joela Mathews for a lively and multiperspective conversation on the topic, with questions from the audience more than welcome.

Webinar objectives

  • To discuss from a multidisciplinary perspective whether the person with MS should be able to switch from low efficacy to a high efficacy disease modifying therapy in the absence of progression or relapse activity.
  • To discuss the likely impact on MS services and if it would result in an increased or decreased in variance of DMT prescribing.
  • Consider some of the challenges in discussions with patients about treatment with moderate and high efficacy treatments.

Agenda

Chair: Dr David Paling

FOR: Dr Sharmilee Gnanapavan

AGAINST: Dr Antonio Scalfari

Round Table Discussion: Dr David Paling, Dr Sharmilee Gnanapavan, Dr Antonio Scalfari, Jennifer Slough & Joela Mathews


This event is free to attend as a result of sponsorship from our sponsors. The current event sponsors are listed on this page. In the interest of Neurology Academy and our sponsors’ legitimate business interests, we make available your name, job title and workplace to our sponsors. It allows us to attract the most appropriate sponsors, delegates and speakers for the events and to facilitate potential collaboration and communication between you and the sponsors; and allows us to offer other relevant events and services to the healthcare and life science industries. You can ask us not to share your name, job title and workplace by emailing info@neurologyacademy.org. We respect the privacy of every person for whom we have personal data. The group privacy and cookies policy can be viewed here.

Book your place now
Our sponsor
Roche logo

This activity has been supported by sponsorship from Roche Products Limited. The sponsor has had no control over the educational content of this activity.

CPD accreditation

'Patients on low-efficacy DMTs should be allowed to switch to a high-efficacy DMT without having to wait for a relapse or progression.' has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 1 category 1 (external) CPD credit(s). Full conditions of approval are listed in our guidelines.

Book your place now
Register now
Encouraging excellence, developing leaders, inspiring change

MS Academy was established five years ago and in that time has accomplished a huge amount. The six different levels of specialist MS training are dedicated to case-based learning and practical application of cutting edge research. Home to national programme Raising the Bar and the fantastic workstream content it is producing, this is an exciting Academy to belong to.